Solara Active Pharma Sciences Limited
NSE: SOLARA BSE: SOLARA
NSE
558.30
-11.55 (-2.03%)
Prev Close
569.85
Open Price
572
Volume
55,069
Today Low / High
556.5 / 581.15
52 WK Low / High
442.8 / 734.4
Range
530 - 586
BSE
559.00
-10.50 (-1.84%)
Prev Close
569.5
Open Price
569.5
Volume
3,941
Today Low / High
556.05 / 571.55
52 WK Low / High
441.1 / 734.2
Range
531 - 587
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 558.3 (target range: 530 - 586), reflecting a change of -11.55 (-2.02685%). On the BSE, it is listed at 559 (target range: 531 - 587), showing a change of -10.5 (-1.84372%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
24 Dec
572.00
-2.40%
23 Dec
570.90
-0.18%
22 Dec
579.60
-1.15%
19 Dec
574.90
-0.19%
18 Dec
590.00
-2.81%
17 Dec
581.00
1.02%
16 Dec
591.15
-0.87%
15 Dec
582.90
1.72%
12 Dec
602.80
-2.04%
11 Dec
601.15
-0.47%
10 Dec
606.60
0.07%
09 Dec
556.95
8.83%
08 Dec
545.80
0.82%
05 Dec
544.55
1.37%
04 Dec
555.00
-0.89%
03 Dec
527.95
5.63%
02 Dec
520.00
0.72%
01 Dec
514.60
1.05%
30 Nov
514.60
1.05%
28 Nov
519.95
-1.10%
27 Nov
523.75
-0.91%
26 Nov
525.00
-0.24%
Solara Active Pharma Sciences Limited Graph
Solara Active Pharma Sciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Solara Active Pharma Sciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 558.30, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 559.00 | 564.59 | 508.13 - 621.05 |
| 570.18 | 456.14 - 684.22 | ||
| 575.77 | 403.04 - 748.50 | ||
| Bearish Scenario | 559.00 | 553.41 | 498.07 - 608.75 |
| 547.82 | 438.26 - 657.38 | ||
| 542.23 | 379.56 - 704.90 |
Overview of Solara Active Pharma Sciences Limited
ISIN
INE624Z01016
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
236,500
Market Cap
23,900,674,492
Last Dividend
0
Official Website
IPO Date
2018-06-27
DCF Diff
1,033.35
DCF
-471
Financial Ratios Every Investor Needs
Stock Dividend of SOLARA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2021-08-18 | August 18, 21 | 3 | 3 | 2021-08-20 | 2021-09-24 | |
| 2020-11-19 | November 19, 20 | 4 | 4 | 2020-11-20 | 2020-12-11 | |
| 2020-07-28 | July 28, 20 | 2 | 2 | 2020-07-29 | 2020-09-03 | 2020-05-07 |
| 2019-08-06 | August 06, 19 | 5 | 5 | 2019-08-07 | 2019-09-13 | 2019-05-16 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,283.76 Cr | 626.41 Cr | 657.35 Cr | 0.5121 | 34.48 Cr | 214.36 Cr | 445.66 Cr | 0.54 Cr | 0.14 | 206.28 Cr | 0.0004 |
| 2024-03-31 | 1,288.92 Cr | 1,403.98 Cr | -129.88 Cr | -0.1008 | 55.98 Cr | 24.33 Cr | -385.29 Cr | -567.39 Cr | -145.27 | -282.19 Cr | -0.4402 |
| 2023-03-31 | 1,426.61 Cr | 1,301.83 Cr | 124.78 Cr | 0.0875 | 46.16 Cr | 229.92 Cr | 8.56 Cr | -22.17 Cr | -6.16 | 152.36 Cr | -0.0155 |
| 2022-03-31 | 1,268.34 Cr | 707.89 Cr | 560.45 Cr | 0.4419 | 65.62 Cr | 238.83 Cr | -33.28 Cr | -58.15 Cr | -16.18 | 79.33 Cr | -0.0458 |
| 2021-03-31 | 1,596.80 Cr | 1,215.62 Cr | 381.18 Cr | 0.2387 | 52.91 Cr | 32.85 Cr | 261.80 Cr | 221.40 Cr | 63.59 | 413.85 Cr | 0.1387 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4.11 Cr | 2,231.84 Cr | 1,134.93 Cr | 1,094.2400 Cr | 796.08 Cr | 791.97 Cr | 317.90 Cr | 1,076.47 Cr | 0.00 Cr | 0.00 Cr | 1.70 Cr | 944.1100 Cr |
| 2024-03-31 | 8.44 Cr | 2,350.96 Cr | 1,414.38 Cr | 933.9100 Cr | 1,011.50 Cr | 1,003.06 Cr | 359.70 Cr | 1,114.22 Cr | 4.19 Cr | 0.00 Cr | 1.70 Cr | 1,242.8500 Cr |
| 2023-03-31 | 8.73 Cr | 2,899.06 Cr | 1,396.60 Cr | 1,500.2200 Cr | 1,012.85 Cr | 1,004.12 Cr | 558.09 Cr | 1,159.05 Cr | 16.01 Cr | -83.31 Cr | 1.70 Cr | 1,100.9000 Cr |
| 2022-03-31 | 46.38 Cr | 2,952.53 Cr | 1,417.78 Cr | 1,524.8700 Cr | 1,037.37 Cr | 990.99 Cr | 575.55 Cr | 1,160.12 Cr | 38.40 Cr | 23.13 Cr | 0.42 Cr | 1,063.4200 Cr |
| 2021-03-31 | 197.69 Cr | 2,613.58 Cr | 1,020.82 Cr | 1,588.5200 Cr | 620.73 Cr | 423.04 Cr | 294.97 Cr | 1,038.86 Cr | 20.29 Cr | 28.49 Cr | -28.20 Cr | 788.7500 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 212.8200 Cr | -36.8300 Cr | -180.4800 Cr | 172.8800 Cr | -4.4900 Cr | 3.9500 Cr | -39.9400 Cr | 0.5400 Cr | -221.3800 Cr | 0.0000 Cr | 41.8000 Cr |
| 2024-03-31 | 108.8700 Cr | -3.5100 Cr | -105.6500 Cr | 67.8100 Cr | -0.2900 Cr | 8.4400 Cr | -41.0600 Cr | -488.4200 Cr | -2.1400 Cr | 0.0000 Cr | 13.0800 Cr |
| 2023-03-31 | 156.2500 Cr | -81.1400 Cr | -112.7600 Cr | 44.9400 Cr | -37.6500 Cr | 8.7300 Cr | -111.3100 Cr | -44.8100 Cr | -22.8800 Cr | 0.0000 Cr | 17.3200 Cr |
| 2022-03-31 | -242.0300 Cr | -242.8500 Cr | 333.5700 Cr | -450.6500 Cr | -151.3100 Cr | 46.3800 Cr | -208.6200 Cr | -91.1000 Cr | 417.3100 Cr | -10.7800 Cr | -280.5800 Cr |
| 2021-03-31 | 155.4600 Cr | -106.3000 Cr | 92.4900 Cr | -19.0200 Cr | 141.6500 Cr | 197.6900 Cr | -174.4800 Cr | 221.5000 Cr | -100.1500 Cr | -19.7300 Cr | -15.2400 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 313.54 Cr | 154.00 Cr | 159.54 Cr | 0.5088 | 10.24 Cr | -10.10 Cr | -2.36 | 35.22 Cr | -0.0322 |
| 2025-06-30 | 319.15 Cr | 146.47 Cr | 172.68 Cr | 0.5411 | 33.44 Cr | 10.52 Cr | 2.46 | 58.00 Cr | 0.0330 |
| 2025-03-31 | 273.01 Cr | 118.09 Cr | 154.92 Cr | 0.5675 | 21.07 Cr | -2.10 Cr | -0.54 | 51.32 Cr | -0.0077 |
| 2024-12-31 | 300.31 Cr | 134.86 Cr | 165.45 Cr | 0.5509 | 33.14 Cr | 8.09 Cr | 2.03 | 59.17 Cr | 0.0269 |
| 2024-09-30 | 346.95 Cr | 249.94 Cr | 97.01 Cr | 0.2796 | 35.97 Cr | 8.01 Cr | 2.54 | 61.63 Cr | 0.0231 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 3.71 Cr | 13.22 Cr | 16.93 Cr | 342.28 Cr | 368.70 Cr | 797.65 Cr | 1,070.61 Cr | 2,293.43 Cr | 1,035.97 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 4.11 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,096.91 Cr |
| 2025-03-31 | 4.11 Cr | 0.00 Cr | 4.11 Cr | 326.59 Cr | 317.90 Cr | 728.73 Cr | 1,076.47 Cr | 2,231.84 Cr | 1,134.93 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 6.07 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,088.69 Cr |
| 2024-09-30 | 6.07 Cr | 0.00 Cr | 6.07 Cr | 383.91 Cr | 289.71 Cr | 759.38 Cr | 1,099.18 Cr | 2,289.78 Cr | 1,201.09 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 10.52 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | -2.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 8.09 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 8.01 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -13.46 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2024-05-15 | May 15, 24 | 217:200 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,737.00 | ₹4,167,644,842,890.00 | ₹2,224,444.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,496.50 | ₹1,724,616,629,970.00 | ₹252,785.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,834.30 | ₹1,297,701,350,592.00 | ₹152,697.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,265.80 | ₹1,053,794,354,145.00 | ₹1,265,207.00 |
| Lupin Limited | LUPIN | ₹2,107.00 | ₹962,475,084,242.00 | ₹473,276.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹917.80 | ₹923,521,556,022.00 | ₹745,138.00 |
| Mankind Pharma Limited | MANKIND | ₹2,193.30 | ₹905,405,364,418.00 | ₹269,608.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,211.40 | ₹703,583,086,102.00 | ₹253,875.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,566.00 | ₹665,498,790,000.00 | ₹41,223.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,084.80 | ₹585,636,420,154.00 | ₹1,708,663.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,020.10 | ₹570,073,854,261.00 | ₹579,252.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,414.70 | ₹358,915,357,205.00 | ₹49,571.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,734.50 | ₹341,636,463,828.00 | ₹1,012,434.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,815.50 | ₹284,399,810,618.00 | ₹47,822.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,411.10 | ₹267,494,959,835.00 | ₹253,413.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,437.00 | ₹233,501,246,853.00 | ₹434,153.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,168.00 | ₹229,200,000,000.00 | ₹4,561.00 |
| Eris Lifesciences Limited | ERIS | ₹1,545.00 | ₹210,455,096,595.00 | ₹30,952.00 |
| Cohance Lifesciences Limited | COHANCE | ₹536.20 | ₹205,132,500,468.00 | ₹297,194.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,086.00 | ₹193,551,705,454.00 | ₹64,393.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,066.60 | ₹169,054,430,771.00 | ₹67,188.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹857.20 | ₹168,493,909,893.00 | ₹41,082.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹916.25 | ₹164,109,418,388.00 | ₹309,335.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,970.10 | ₹149,750,642,290.00 | ₹16,243.00 |
| Granules India Limited | GRANULES | ₹612.40 | ₹148,610,321,678.00 | ₹3,335,314.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹904.65 | ₹110,983,681,468.00 | ₹21,653.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,641.00 | ₹93,637,113,862.00 | ₹2,377.00 |
| Strides Pharma Science Limited | STAR | ₹938.30 | ₹86,485,657,546.00 | ₹168,043.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹759.80 | ₹68,873,813,981.00 | ₹89,640.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹446.30 | ₹68,329,448,485.00 | ₹179,190.00 |
| FDC Limited | FDC | ₹409.15 | ₹66,613,745,869.00 | ₹37,886.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹318.80 | ₹62,351,482,941.00 | ₹177,808.00 |
| Sequent Scientific Limited | SEQUENT | ₹213.86 | ₹53,427,321,931.00 | ₹430,552.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹437.80 | ₹47,704,993,017.00 | ₹1,374,079.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹135.61 | ₹44,008,372,549.00 | ₹827,096.00 |
| Innova Captab Limited | INNOVACAP | ₹714.95 | ₹40,912,962,989.00 | ₹16,795.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹772.40 | ₹39,175,436,702.00 | ₹30,197.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,352.30 | ₹38,904,724,985.00 | ₹2,228.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹422.00 | ₹38,515,940,000.00 | ₹417,255.00 |
| Suven Life Sciences Limited | SUVEN | ₹167.61 | ₹36,942,252,174.00 | ₹95,828.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹342.15 | ₹34,311,659,428.00 | ₹18,106.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹448.55 | ₹31,580,499,163.00 | ₹18,057.00 |
| Hikal Limited | HIKAL | ₹238.15 | ₹29,364,073,613.00 | ₹452,521.00 |
Key Executives
Whole Time Director & COO
Mohan Muthunarayanan
Gender: male
Year Born: 1972
Chief Human Resources Officer
Mohanraj S
Gender: male
Year Born:
Chief Risk Officer
Rajesh Patro
Gender: male
Year Born:
Chief Quality Officer
V. Sundara Moorthy
Gender: male
Year Born:
Company Secretary & Compliance Officer
Pooja Jaya Kumar
Gender: female
Year Born:
Chief Scientific Officer
Hero Velladurai
Gender: Not Specified
Year Born:
Founder & Non-Executive Director
Arun Kumar Pillai
Gender: male
Year Born: 1961
General Manager of Accounts
Raghavan Venkatramani
Gender: male
Year Born:
CEO & MD
Sandeep Rao
Gender: male
Year Born: 1973
Chief Financial Officer & Chief Investor Relations Officer
Sarat Kumar
Gender: male
Year Born:
Chief Commercial Officer
Vishal Mathur
Gender: male
Year Born:
FAQs about Solara Active Pharma Sciences Limited
Who is the CEO of the company?
The CEO is Sandeep Shashikantha Rao.
What is the current market price of the stock?
The current price is ₹558.30.
What is the 52-week price range?
The range is ₹442.8-734.4.
What is the market capitalization of the company?
The market capitalization is ₹2,390.07 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 372.75.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Solara Active Pharma Sciences Limited (ISIN: INE624Z01016) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹2,390.07 crores and an average daily volume of 236,500 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.